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GPR18, still considered an orphan receptor, may respond to endocannabinoids, whose 
canonical receptors are CB1 and CB2. GPR18 and CB2 receptors share a role in peripheral 
immune response regulation and are co-expressed in microglia, which are immunocompetent 
cells in the central nervous system (CNS). We aimed at identifying heteroreceptor complexes 
formed by GPR18 and CB1R or CB2R in resting and activated microglia. Receptor-receptor 
interaction was assessed using energy-transfer approaches, and receptor function by 
determining cAMP levels and ERK1/2 phosphorylation in heterologous cells and primary 
cultures of microglia. Heteroreceptor identification in primary cultures of microglia was 
achieved by in situ proximity ligation assays. Energy transfer results showed interaction of 
GPR18 with CB2R but not with CB1R. CB2-GPR18 heteroreceptor complexes displayed 
particular functional properties (heteromer prints) often consisting of negative cross-talk 
(activation of one receptor reduces signaling arising from the partner receptor) and cross-
antagonism (the response of one of the receptors is blocked by a selective antagonist of the 
partner receptor). Activated microglia showed the heteromer print (negative cross-talk and 
bidirectional cross-antagonism) and increased expression of CB2R and GPR18. Due to the 
important role of CB2R in neuroprotection, we further investigated heteroreceptor occurrence 
in primary cultures of microglia from transgenic mice overexpressing human APPSw,Ind, an 
Alzheimer’s disease model. Microglial cells from transgenic mice showed the heteromer print 
and functional interactions that were similar to those found in cells from wild-type animals 
that were activated by treatment with lipopolysaccharide and interferon-ɤ. Our results show 










2-AG: 2- arachidonoylglycerol, Abn-CBD: abnormal cannabidiol, AD: Alzheimer’s disease, 
AEA: anandamide, CB1R: cannabinoid receptor 1, CB2R: cannabinoid receptor 2, CNS: 
central nervous system, ERK1/2: extracellular signal-regulated kinase 1/2, MAPK: mitogen-
activated protein kinase; NAGLy: N-arachidonoylglycine, PLA: proximity ligation assay, 










GPR18, a GPCR discovered in 1997 (Gantz et al., 1997), is still an orphan receptor although 
some agonists have been reported. Abnormal cannabidiol (Abn-CBD) is a nonselective 
GPR18 agonist (Franklin and Stella, 2003); for this reason GPR18 is also known as Abn-CBD 
receptor. N-arachidonoylglycine (NAGly), which arises from anandamide (AEA; N-
arachidonoylethanolamine) metabolism (Bradshaw et al., 2009), was suggested by (Kohno et 
al., 2006) and later by (McHugh et al., 2010; Takenouchi et al., 2012; Console-Bram et al., 
2014) as the endogenous ligand. In contrast, some authors describe GPR18 as unresponsive to 
NAGly (Lu et al., 2013; Rempel et al., 2014; Finlay et al., 2016). The receptor became of 
interest in the cannabinoid research field because cannabinoids may activate it (Járai et al., 
1999). In summary, despite potential activation by endocannabinoids and NAGly, GPCR18 
still remains as an orphan receptor (IUPHAR/BPS: www.guidetopharmacology.org). 
GPR18 is widely expressed in different tissues and cell types. GPR18 expression was first 
described in spleen, thymus, bone marrow, leucocytes and macrophages (Gantz et al., 1997; 
Vassilatis et al., 2003; Kohno et al., 2006; Regard et al., 2008; Takenouchi et al., 2012; 
Becker et al., 2015). However, receptor is also expressed in the central nervous system (CNS) 
(Vassilatis et al., 2003; Regard et al., 2008; Penumarti and Abdel-Rahman, 2014), in 
particular in microglia (Walter et al., 2003), in testis, ovary, lungs, intestine (Gantz et al., 
1997; Vassilatis et al., 2003), eye (Caldwell et al., 2013) and cancerous cells (McHugh et al., 
2010, 2012; Qin et al., 2011).  
In the periphery, regulating the immune system, GPR18 is involved in resolving inflammation 
(Burstein et al., 2011), regulating macrophage apoptosis (Takenouchi et al., 2012) and 
controlling the fate of intestine intraepithelial lymphocytes following bone marrow 
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transplantation (Becker et al., 2015). It is also involved in regulating hemodynamic responses 
(Parmar and Ho, 2010; Penumarti and Abdel-Rahman, 2014; Al Suleimani and Al Mahruqi, 
2017; Matouk et al., 2017), cell migration (Walter et al., 2003; McHugh et al., 2010) and 
intraocular pressure (Miller et al., 2016). Furthermore, its activation produce analgesia (Jeong 
et al., 2010). 
GPR18 is a Gi/o coupled receptor, as pertussis toxin (PTX) is able to block the decrease of 
intracellular cAMP levels elicited by one of the reported agonists, NAGly (Kohno et al., 
2006). Intriguingly, it has been described that NAGly, Δ
9
-THC and Abn-CBD may increase 
intracellular Ca
2+
 levels via GPR18, thus suggesting that the receptor is also able to couple to 
Gq (Kohno et al., 2006; Bradshaw et al., 2009). In addition, activation of GPR18 by NAGly, 
Δ
9
-THC or Abn-CBD may lead to engagement of the MAP kinase pathway in a PTX-
dependent fashion (McHugh et al., 2010; Takenouchi et al., 2012). Only Δ
9
-THC has been 
found to recruit ß-arrestins (Yin et al., 2009; Rempel et al., 2014), thus suggesting that the 
receptor is prone to a markedly biased agonism depending on the structure of the ligand used 
in the assays. 
Endocannabinoids, and natural and synthetic cannabinoids act via specific CB1 and CB2 
cannabinoid receptors (Lu and Mackie, 2016). Activation of cannabinoid receptors (CB1R and 
CB2R), which are coupled to Gi proteins, leads to an inhibition of adenylate cyclase and a 
decrease in the intracellular levels of a second messenger, cAMP. The CB1R is considered as 
the most abundant GPCR in the CNS, being present in neurons and in glia (Bilkei-Gorzo, 
2012); in the CNS the CB2R is expressed in neurons in some restricted brain areas (see 
(Lanciego et al., 2011) and references therein) and in glia, mainly in activated  microglia 
(Cabral and Marciano-Cabral, 2005; Fernández-Ruiz et al., 2007). Cannabinoid receptors may 
establish direct interactions and this may occur in some neurons of the globus pallidus where 
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the two receptors are co-expressed (Callén et al., 2012; Sierra et al., 2015), and in glial cells 
(Navarro et al., 2018a).  
 
Some authors have described that CB2R and GPR18 may work in cooperation to regulate 
microglial cell migration (Franklin and Stella, 2003; Walter et al., 2003). As demonstrated for 
an increasing number of GPCRs, CB1R and CB2R may establish receptor-receptor 
interactions leading to CB1R-CB2R heteromers displaying particular characteristics and with 
impact on neural regulation of neurotransmission and neuroinflammation (Callén et al., 2012; 
Navarro et al., 2018a). The two aims of this investigation were to look for potential 
interactions of GPR18 with cannabinoid CB1 and/or CB2 receptors, with a special focus on 
the CNS, where all three GPCRs are expressed, and to look for the physiological significance 
of CB1R/CB2R-GPR18 heteromer expression and signaling in activated microglial cells, as 
microglia are the immune competent cells in the CNS. We identified the occurrence of CB2R-
GPR18 heteroreceptor complexes in a heterologous expression system and in primary cultures 
of microglia in resting conditions and upon activation with LPS and IFN-γ. Functional assays 
were performed to detect the heteromer print, which was also identified in primary cultures of 
microglia from a transgenic mouse model of Alzheimer’s disease. Microglial cells from the 
brain of transgenic mice expressed CB2R-GPR18 receptor complexes that behaved like those 
in cells from wild-type animals treated with LPS and IFN-γ. These results highlight the 
potential of GPR18 and CB2 receptors in microglia for modulating or regulating 
neurodegeneration and neuroprotection. 
 
2. MATERIALS AND METHODS 
2.1. Expression vectors  
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cDNAs for the human version of CB1, CB2, GPR18 and GABAB receptors with sequences 
lacking the stop codon were obtained by PCR and subcloned to Rluc-containing vector 
(pRluc-N1; PerkinElmer, Wellesley, MA) using sense and antisense primers harboring unique 
restriction sites for HindIII and BamHI, to generate CB1R-Rluc, GPR18-Rluc and GABAB-
Rluc fusion proteins, or subcloned to enhanced yellow fluorescent protein-containing vector 
(pEYFP-N1; Clontech, Heidelberg, Germany) using sense and antisense primers harboring 
unique restriction sites for BamHI and KpnI, to generate CB1R-YFP and CB2R-YFP fusion 
proteins, or using sense and antisense primers harboring unique restriction sites for BamHI 
and HindIII, to generate GPR18-YFP fusion protein.  
2.2. Transgenic mouse model of Alzheimer’s disease (AD)  
APPSw,Ind transgenic mice (line J9; C57BL/6 background) expressing human APP695 
harboring the familial Alzheimer´s disease-linked Swedish (K670N/M671L) and Indiana 
(V717F) mutations under the PDGFβ promoter were obtained by crossing heterozygous 
APPSw,Ind with wild-type (WT) mice (Mucke et al., 2000). Mice at 2 days of age were 
genotyped individually by conventional PCR (España et al., 2010; Navarro et al., 2018a). 
 Experimental procedures were conducted according to the Animal and Human Ethical 
Committee of the Universitat Autònoma de Barcelona (protocol CEEAH 1783, Generalitat 
Catalunya 6381) following the European Union guidelines. Experiments with primary 
cultures (see below) were performed blindly, without knowing the genotype, which was 
disclosed for data analysis.  
2.3. Cell culture and transient transfection 
HEK-293T cells at passage 8-12 were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco, Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin, MEM Non-Essential Amino Acids Solution (1/100) and 50% (v/v) 
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heat inactivated Fetal Bovine Serum (FBS) (Invitrogen, Paisley, Scotland, UK). Cells were 
maintained in a humid atmosphere of 5% CO2 at 37ºC. Cells were transiently transfected with 
the PEI (PolyEthylenImine, SigmaAldrich) method as previously described (Navarro et al., 
2012). To prepare primary microglial cultures, brain was removed from C57BL/6 or APPSw,Ind 
mice of 2 days of age. Microglial cells, with a purity >95% purity (according to Iba-1 
immunoreactivity and Hoechst nuclei staining) were isolated as described elsewhere (Navarro 
et al., 2018a) and grown in DMEM medium supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin/streptomycin, MEM Non-Essential Amino Acids Solution (1/100) and 5% (v/v) 
heat inactivated Fetal Bovine Serum (FBS) (Invitrogen, Paisley, Scotland, UK). In brief, 
samples were dissected, carefully stripped off the meninges and digested with 0.25% trypsin 
for 30 min at 37ºC. Trypsinization was stopped by adding an equal volume of culture medium 
(Dulbecco’s modified Eagle medium-F-12 nutrient mixture, fetal bovine serum 10%, 
penicillin 100 U/mL, streptomycin 100 µg/mL and amphotericin B 0.5 µg/ml) containing 160 
mg/mL deoxyribonuclease I (all those reagents from Invitrogen). Cells were brought to a 
homogeneous suspension by repeated pipetting followed by passage through a 100 µm-pore 
mesh and pelleted (7 min, 200 x g). Glial cells were resuspended in medium and seeded at a 
density of 3.5 x 10
5
 cell/ml in 6-well plates. Cultures were maintained at 37ºC in humid 5% 
CO2 atmosphere and medium was replaced at DIV 2 and once every week. For other assays 
cells were grown either in 6-well plates at a density of 500,000/well in 2 mL or directly in 96-
well plates at a density of 50,000/well; each well having a volume of 0.2 ml. For cAMP 
assays, cells grown on 6-well plates were scrapped and placed in 384-well plates at a density 
of 2,500 cells/well. Cell counting was assessed using trypan blue and a Countless II FL 
automated cell counter (Thermo Fisher Scientific-Life Technologies).  
Bioluminescence resonance energy transfer (BRET) assays 
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HEK-293T cells growing in 6-well plates were transiently cotransfected with a constant 
amount of cDNA encoding for CB1-Rluc, GPR18-Rluc or GABAB-Rluc and with increasing 
amounts of cDNA corresponding to CB2-YFP, CB1-YFP or CB2-YFP and GPR18-YFP, 
respectively. 48 h post transfection cells were washed twice in quick succession in HBSS 
(137 mM NaCl; 5 mM KCl; 0.34 mM Na2HPO4; 0.44 mM KH2PO4; 1.26 mM CaCl2; 0.4 mM 
MgSO4; 0.5 mM MgCl2; and 10 mM HEPES pH 7.4) supplemented with 0.1% glucose (w v-
1), detached by gently pipetting and resuspended in the same buffer. To assess the amount of 
cells per plate, protein concentration was determined using a Bradford assay kit (Bio-Rad, 
Munich, Germany) using bovine serum albumin dilutions as standards. To quantify YFP-
fluorescence expression, cells (20 μg protein) were distributed in 96-well plates (black plates 
with a transparent bottom; Porvair, Leatherhead, UK) and fluorescence was read using a 
Mithras LB 940 (Berthold, Bad Wildbad, Germany) equipped with a high-energy xenon flash 
lamp, using a 10-nm bandwidth excitation and emission filters at 485 and 530 nm, 
respectively. YFP-fluorescence expression was determined as fluorescence of the sample 
minus the fluorescence of cells expressing protein-Rluc alone. For BRET measurements, the 
equivalent of 20 μg of cell suspension was distributed in 96-well plates (white plates; Porvair) 
and 5 μM coelenterazine H (PJK GMBH, Kleinblittersdorf, Germany) was added. 1 min after 
coelenterazine H addition, readings were collected using a Mithras LB 940 (Berthold, Bad 
Wildbad, Germany), which allows the integration of the signals detected in the short-
wavelength filter at 485 nm (440–500 nm) and the long-wavelength filter at 530 nm (510–590 
nm). To quantify receptor-Rluc expression, luminescence readings were performed 10 min 
after 5 μM coelenterazine H addition. The net BRET is defined as [(long-wavelength 
emission)/(short-wavelength emission)]-Cf where Cf corresponds to [(long-wavelength 
emission)/(short-wavelength emission)] for the Rluc construct expressed alone in the same 
experiment. BRET curves were fitted assuming a single phase by non-linear regression 
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equation using the GraphPad Prism software (San Diego, CA, USA). BRET values are given 
as milli BRET units (mBU: 1,000 x net BRET). 
2.4. Immunostaining procedures 
Cells were fixed in 4% paraformaldehyde for 15 min and washed twice with PBS containing 
20 mM glycine before permeabilization with PBS-glycine containing 0.2% Triton X-100 (5 
min incubation). HEK-293T cells were treated for 1 h with PBS containing 1% bovine serum 
albumin and labelled with a mouse anti-Rluc (1/100; MAB4400, Millipore) antibody, and 
subsequently treated with Cy3-conjugated anti-mouse (1/200; 715-166-150; Jackson 
ImmunoResearch (red)) IgG secondary antibody (1 h each). Specificity of antibodies was 
tested in untransfected HEK-293T cells (data not shown). Samples were washed several times 
and mounted with 30% Mowiol (Calbiochem). Samples were observed in a Leica SP2 
confocal microscope (Leica Microsystems).  
2.5. cAMP determination 
Two hours before adding reagents, HEK-293T cells or microglial primary cultures were 
placed in serum-free medium. Then, cells were detached and suspended in medium containing 
50 µM zardaverine. Cells were placed in 384-well plates (2,500 cells/well), pretreated (15 
min) with the corresponding antagonists -or vehicle- and stimulated with agonists (15 min) 
before adding 0.5 µM forskolin or vehicle (15 min). Readings were performed after 1 h of 
incubation at 25ºC. Homogeneous time-resolved fluorescence energy transfer (HTRF) 
measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, 
USA). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship plate reader equipped 
with an HTRF optical module (BMG Lab technologies, Offenburg, Germany). The value of 
reference (100%) was that achieved by 0.5 µM forskolin treatment. The effect of ligands was 
given in percentage respect to the reference value. 
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2.6. ERK phosphorylation assays 
To determine ERK1/2 phosphorylation, 40,000 cells/well were plated in transparent Deltalab 
96-well plates and kept at the incubator for 48 h. 2 to 4 h before the experiment, the medium 
was replaced by serum-free medium. Then, cells were pre-treated at 25°C for 10 min with 
vehicle or antagonists in serum-free DMEM medium and stimulated for an additional 7 min 
with agonists. Cells were then washed twice with cold PBS before addition of lysis buffer (20 
min treatment). 10 µL of each supernatant were placed in white ProxiPlate 384-well plates 




 kit (Perkin 
Elmer) following the instructions of the supplier and using an EnSpire
® 
Multimode Plate 
Reader (PerkinElmer, Waltham, MA, USA). The value of reference (100%) was that achieved 
in the absence of any treatment (basal). The effect of ligands was given in percentage respect 
to the basal value. 
2.7. Dynamic mass redistribution (DMR) assays  
Cell mass redistribution induced upon receptor activation was detected by illuminating with 
polychromatic light the underside of a biosensor and measuring the changes in the wavelength 
of the reflected monochromatic light that is a sensitive function of the index of refraction. The 
magnitude of the wavelength shift (in picometers) is directly proportional to the amount of 
mass redistribution. HEK-293T cells were seeded in 384-well sensor microplates to obtain 
70-80% confluent monolayers constituted by approximately 10,000 cells per well. Previous to 
the assay, cells were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) 
and incubated 2 h with assay-buffer containing 0.1% DMSO (24°C, 30 µL/well). Hereafter, 
the sensor plate was scanned and a baseline optical signature was recorded for 10 min before 
adding 10 µL of the selective antagonists for 30 min followed by the addition of 10 µL of the 
selective agonists; all test compounds were dissolved in assay buffer. Then, DMR responses 
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were monitored for at least 5,000 s in an EnSpire® Multimode Plate Reader (PerkinElmer, 
Waltham, MA, USA). Results were analyzed using EnSpire Workstation Software v 4.10. 
2.8.  In situ proximity ligation assays (PLA) 
Microglial primary cultures grown on glass coverslips were fixed in 4% paraformaldehyde for 
15 min, washed with PBS containing 20 mM glycine to quench the aldehyde groups and 
permeabilized with the same buffer containing 0.05% Triton X-100 (5 min treatment). Fixed 
cells were incubated for 1 h at 37º with blocking solution (from PLA kit, see below) and 
subsequently treated with specific antibodies against CB2 (SC-25494 raised in rabbit; 1/100) 
and GPR18 (SC-79501, raised in goat; 1/100) receptors and processed using the PLA probes 
detecting rabbit and goat antibodies (Duolink II PLA probe anti-Rabbit plus and Duolink II 
PLA probe anti-Goat minus). Specificity of antibodies was tested in untransfected HEK-293T 
cells (data not shown). Duolink II in situ PLA detection kit (Duolink
®
 In Situ Detection 
Reagents Red, DUO92008, developed by Olink Bioscience, Uppsala, Sweden; and now 
distributed by SigmaAldrich as Duolink® using PLA® Technology) was used to detect the 
presence/absence of receptor clusters in the samples, which were incubated with the ligation 
solution for 1 hour, washed and subsequently incubated with the amplification solution for 
100 min (both steps at 37°C in a humid chamber). Nuclei were stained with Hoechst (1/100; 
SigmaAldrich). Mounting was performed using 30% Mowiol (Calbiochem). Negative 
controls were performed by omitting the primary anti-GPR18 antibody. Samples were 
observed in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany) 
equipped with an apochromatic 63X oil-immersion objective (N.A. 1.4), and 405 nm and 561 
nm laser lines. For each field of view a stack of two channels (one per staining) and 5 Z stacks 
with a step size of 1 µm were acquired. The number of cells containing one or more red spots 
versus total cells (blue nucleus) and, in cells containing spots, the ratio r (number of red 
spots/cell), were determined by means of the Duolink Image tool software.  
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2.9.Real time (RT)-PCR assay  
Total RNA was extracted from primary cultures of microglial cells treated for 48 h with 
vehicle (cell culture medium) or LPS plus IFN-γ (in medium). Pelleted microglial cells were 
treated with 1.5 mL of TRIzol Reagent (Thermo Fisher) and 300 µl of chloroform 
(SigmaAldrich). The aqueous phase containing total RNA was recovered after centrifugation 
for 15 min at 12,000 x g at 4ºC, mixed with 750 µl of isopropanol (Panreac) and left overnight 
at -80ºC. Total RNA was then purified by centrifugation at 12,000 x g at 4ºC (15 min), 
washing the pellet with 70 % ethanol (Panreac) and suspending the final pellet in Milli-Q 
water. Total RNA was quantified spectrophotometrically using a Nano Drop ND-1000 
(Thermo Scientific). Total RNA (1 µg) was reversely transcribed by random priming using 
the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Foster City, 
CA, USA). The resulting single stranded cDNA was used to perform PCR amplification for 
CB2R, and for GAPDH as an internal control using Power SYBR Green PCR Master Mix 
from Promega (Madison, WI, USA). Fluorescence readouts were collected using a 7500 
Fast  Dx Real-Time PCR Instrument  from Applied Biosystems (Foster City, CA, 
USA). CB2R forward primer was: 5’-CATCACTGCCTGGCTCACT-3’ and reverse primer 
was: 5’- AGCATAGTCCTCGGTCCTCA-3’. In the case of GPR18, the forward primer was: 
5’-TGAAGCCCAAGGTCAAGGAGAAGT-3’ and the reverse primer was: 5’-
TTCATGAGGAAGGTGGTGAAGGCT-3’. In the case of GAPDH the forward/reverse 
primers were, respectively, 5’-CATCCTGCACCACCAACTGCTTAG-3’ and 5’- 
GCCTGCTTCACCACCTTCTTGATG-3’. In the absence of reverse transcription, no 
fluorescence was detected, thus indicating that there was no genomic DNA contamination. 
MIQUE guidelines were followed. 
 
2.10. Data analysis 
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The data in graphs are the mean ± S.D. GraphPad Prism software version 5 (San Diego, CA, 
USA) was used for data fitting and statistical analysis. One- or two-way ANOVA followed by 
post-hoc Bonferroni test were used depending of the number of factors. Two factors were 
considered in the case of ligand treatments (8 levels) in resting or activated cells (two levels) 
or in the case of ligand treatments in microglia from control or transgenic mice (two levels). 
PLA data in Fig. 5 were analyzed using two-way ANOVA with two levels for each factor 
(negative/positive and control/transgenic). When pair of values were compared, the Student’s 




LPS and interferon-γ (IFN-γ) were purchased from SigmaAldrich (St Louis, MO, USA) and 
ACEA, JWH133 and AM630 from Tocris Bioscience (Bristol, UK). PSBKK1415 and 
PSBCB5 were synthesized in the Department of Technology and Biotechnology of Drugs, 
Jagiellonian University Cracow, Poland, and provided by Prof. Christa Müller, PharmaCenter 
Bonn, Bonn (Rempel et al., 2014; Schoeder, 2017). 
 
3. RESULTS  
3.1. GPR18 interacts with cannabinoid CB2 but not with CB1 receptors 
To determine whether GPR18, which belongs to the superfamily of G-protein-coupled 
receptors, could form heteromeric complexes with cannabinoid CB1 or CB2 receptors, an 
immunocytochemistry assay was first developed to assess the potential colocalization of 
GPR18 and cannabinoid receptors in cotransfected cells. To do so, the heterologous HEK-
293T cell-expression system was used. Cells were transfected with cDNAs for CB1R-YFP 
(green, top left panel in Fig. 1A), CB2R-YFP (green, top center panel in Fig. 1A) or GPR18-
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Rluc (red, top right panel in Fig. 1A). Receptor expression was detected by YFP’s own 
fluorescence for CB1R and CB2R, or using an anti-Rluc antibody and a secondary Cy3-
conjugated antibody for GPR18. As observed in Figure 1A, all three receptors were found in 
different cell locations including the plasma membrane. Moreover, when HEK-293T cells 
were transfected with cDNAs for GPR18-Rluc and either CB1R-YFP or CB2R-YFP, both 
GPR18/CB1R and GPR18/CB2R showed a significant degree of co-localization (Fig. 1A). 
Indeed, co-localization does not prove a direct interaction; hence, to demonstrate physical 
interactions between receptor pairs, a bioluminescence resonance energy transfer (BRET) 
approach was used. We checked that all cannabinoid and GPR18 receptor-fusion proteins 
properly trafficked to the cell membrane, as shown by confocal microscopy, and were 
functional, as shown by similar ability to decrease forskolin-induced cAMP levels as that of 
native proteins (Fig. 1B). BRET was undertaken in HEK-293T cells expressing a constant 
amount of cDNA for GPR18-Rluc and increasing amounts of cDNA for CB1R-YFP. An 
unspecific linear signal was obtained, indicating the lack of interaction between CB1 and 
GPR18 receptors (Fig. 1C). A similar linear relationship was obtained for the negative control 
consisting of HEK-293T cells expressing a constant amount of GABABR-Rluc and increasing 
amounts of GPR18-YFP (Fig. 1E). However, when a similar experiment was developed 
transfecting HEK-293T cells with a constant amount of cDNA for GPR18-Rluc and 
increasing amounts of cDNA for CB2R-YFP, a saturation BRET curve (BRETmax 227 mBU, 
BRET50 47.5) was obtained, thus indicating a specific interaction between GPR18 and CB2 
receptors (Fig. 1D). As positive control, a saturation BRET curve (BRETmax 57.9 mBU, 
BRET50 4.28) was obtained in HEK-293T cells expressing CB1R-Rluc and increasing 
amounts of CB2R-YFP (Fig. 1E). These results indicate that GPR18 may form heteroreceptor 
complexes with CB2 but not with CB1 receptors. 
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3.2. Functional characterization of CB2-GPR18 heteroreceptor complexes in HEK-
293T cells 
It is well established that CB2R couples to heterotrimeric Gi proteins and its activation inhibits 
adenylate cyclase thus decreasing intracellular cAMP levels (Lu and Mackie, 2016). Some 
authors have reported that GPR18 may also couple to Gi (Kohno et al., 2006). Accordingly, 
we first determined cAMP levels in forskolin-treated HEK-293T cells expressing CB2R, 
GPR18 or both. Agonist concentrations were selected from preliminary dose-response 
experiments in which the ability of JWH133 or PSBKK1415 to decrease forskolin-induced 
cAMP levels was assayed using HEK-293T cells expressing, respectively, CB2R or GPR18 
(Fig. 2A-B). On the one hand, the selective CB2R agonist, JWH133 (100 nM), decreased 
forskolin-induced cAMP levels in HEK-293T cells expressing the receptor, and induced a 
small non-statistically significant effect in cells expressing GPR18 (Fig. 3A-B). On the other 
hand, PSBKK1415 (30 nM), a selective GPR18 agonist, induced a significant decrease in 
cAMP levels in forskolin-treated HEK-293T cells expressing the receptor, while having no 
effect in CB2R-expressing cells (Fig. 3A-B). Moreover, the CB2R selective antagonist, 
SR144528 (1 µM) inhibited the JWH133 induced effect in CB2R-expressing cells (Fig. 3A), 
while PSBCB5 (1 µM), a selective GPR18 receptor antagonist, counteracted the 
PSBKK1415-induced effect in GPR18-expressing cells (Fig. 3B). In HEK-293T cells 
expressing both CB2 and GPR18 receptors, JWH133 decreased cAMP levels in a similar 
manner to that observed in cells only expressing CB2R. In contrast, the treatment with 
PSBKK1415 was ineffective, thus suggesting that the simple expression of CB2R blocks the 
PSBKK1415-induced GPR18 activation and signaling. Finally, when cotransfected cells were 
simultaneously treated with the two agonists, no effect was observed (Fig. 3C). A negative 
cross-talk may be used as a print to detect the GPR18-CB2 heteroreceptor complexes in 
natural sources. Although the pretreatment with GPR18 receptor antagonist PSBCB5 (1 µM) 
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slightly decreased the JWH133 induced effect in cotransfected cells, no significant differences 
were found compared to the single treatment with JWH133 (Fig. 3C).   
MAPK engagement, which may be mediated by G-protein-independent mechanisms, was also 
analyzed. Agonist concentrations were selected from dose-response experiments of JWH133 
or PSBKK1415 treatments in which ERK1/2 phosphorylation in HEK-293T cells expressing 
CB2R or GPR18, respectively, was tested (Fig. 2C-D). In CB2R-expressing HEK-293T cells it 
JWH133 specifically increased ERK1/2 phosphorylation, while PSBKK1415 induced no 
effect (Fig. 3D). In GPR18-expressing cells, PSBKK1415 (30 nM) induced a significant 
effect while the CB2R selective agonist had no effect (Fig. 3E). In HEK-293T cells expressing 
the two receptors both JWH133 and PSBKK1415 induced a small effect when used 
individually that was reduced when used in combination (Fig. 3F). Accordingly, a negative 
cross-talk was also observed in MAPK signaling. Interestingly, in cotransfected cells 
pretreated with the selective CB2R antagonist SR144528 (1 µM) or with the selective GPR18 
receptor antagonist PSBCB5 (1 µM), the effect of both JWH133 and PSBKK1415 on ERK1/2 
phosphorylation was counteracted, thus a cross-antagonism effect was detected on both 
directions (Fig. 3F). Uni- or bi-directional cross-antagonism constitute reliable heteromer 
prints. DMR, which is a label-free method to measure cellular mass movements induced upon 
receptor activation, was determined in cells expressing either receptor. JWH133 or 
PSBKK1415 provided significant real-time DMR recordings by, respectively, activating 
CB2R or GPR18 receptors (Fig. 3G-H). Interestingly, the cross-talk and cross-antagonism 
detected in cAMP determination and MAPK signaling assays were also observed in cells 
expressing both receptors (Fig. 3I). 
These results show receptor heteromerization and a functional cross-talk that is due to the 
molecular interaction and that is disclosed by negative cross-talk and/or cross-antagonism 
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3.3. Functional characterization of CB2-GPR18 heteroreceptor complexes in primary 
cultures of microglia 
Our next aim was to address the physiological relevance of the finding of heteromers in a 
heterologous expression system. Accordingly, we performed assays to identify heteroreceptor 
complexes in in primary cultures of microglia. Proximity ligation assays (PLA) were 
performed using specific antibodies against cannabinoid CB2 and GPR18 receptors (see 
Methods) and punctuated red marks were visualized surrounding DAPI-stained nuclei, 
demonstrating the existence of CB2-GPR18 receptor complexes/clusters. The absence of the 
primary anti-GPR18 antibody led to a marked reduction of the PLA signal (Fig. 4A-B, 
untreated). To get insights into the functional role of CB2R-GPR18 heteroreceptor complexes 
in microglial cells, cAMP intracellular levels and MAPK pathway activation were 
determined. In both assay types, treatment of microglia with JWH133 or PSBKK1415 
induced a significant effect that was decreased when the cells were simultaneously treated 
with both ligands. Then, a negative cross-talk was also detected in primary cultures of 
microglia (Fig. 4D-E, untreated). Moreover, pretreatment of the primary cultures with the 
selective GPR18 antagonist PSBCB5 (1 µM) counteracted not only the PSBKK1415-induced 
ERK1/2 phosphorylation, but also the JWH133-induced effect. Cross-antagonism was also 
detected when SR144528 was used as it blocked both JWH133 and PSBKK1415 actions (Fig. 
4E). Thus, cross-antagonism was also detected in resting microglia.  
3.4. GPR18-CB2R negative cross-modulation in activated microglia  
It has been described that CB2R expression increases in activated microglia and that the 
receptor then plays a relevant role in regulating the production of neuroinflammatory 
mediators (Pacher and Mechoulam, 2011; Navarro et al., 2018a). Our next aim was to assess 
the structural and functional implication of CB2-GPR18 heteroreceptor complexes in primary 
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microglia activated by 48-h treatment with 1 µM LPS plus 200 U/mL IFN-γ (see (Navarro et 
al., 2018a)). The relative expression of transcripts for both CB2R and GPR18 was analyzed by 
RT-PCR in microglia from wild type mice treated or not with LPS plus IFN-γ. mRNA 
specific for either CB2R or GPR18 significantly increased in activated cells (Fig. 4C). By 
comparing microglial primary cultures treated or not with 1 μM LPS plus 200 U/mL IFN-γ, 
PLA results showed CB2-GPR18 receptor heteromer expression in both resting and activated 
cells (Fig. 4A-B). We then determined the effect of agonists on cAMP levels and ERK1/2 
phosphorylation. Interestingly, microglia treated with 1 μM LPS plus 200 U/mL IFN-γ 
showed an increase in CB2R- and GPR18-induced signaling. The statistical analysis showed 
an interaction between cell activation (LPS plus IFN-γ) and receptor activation by agonists. 
While all the functional results showed a negative cross-talk, cross-antagonism (bidirectional) 
was identified in pERK but not in cAMP assays (Fig. 4D-E). 
3.5. CB2R-GPR18 heteromer expression and function assayed in primary microglia 
from APPSw,Ind transgenic mice 
Two-day-old pups obtained from APPSw,Ind x WT mice crossings were individually genotyped 
and classified as non-transgenic (control) or heterozygous APP transgenic mice (APPSw,Ind). In 
adulthood the APPSw,Ind mouse displays brain amyloid plaques and neuroinflammatory 
responses, including reactive microglia and cognitive deficits (Mucke et al., 2000). Primary 
cultures of microglia were prepared from both control and APPSw,Ind mice. It should be noted 
that microglia from  APPSw,Ind do show an activated phenotype (see (Navarro et al., 2018a)). 
To detect differential expression in CB2-GPR18 receptor complexes in control and transgenic 
animals, PLA assays were developed using primary cultures of microglia obtained from 
control and APPSw,Ind mice. Significant differences were found between wild-type and 
APPSw,Ind  mice both in the percentage of cells displaying red clusters (61% in control vs 73% 
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in APPSw,Ind mice) and in the number of dots/cell in cells displaying dots (3.5 in control vs 5.0 
in APPSw,Ind mice) (Fig. 5A-B).  
Cultures were also used to determine signaling upon agonist activation. We first analyzed the 
cAMP levels in forskolin-treated primary cultures of microglia from non-transgenic and 
APPSw,Ind mice. Activation with the CB2R selective agonist (JWH133, 300 nM) or with the 
GPR18 selective agonist (PSBKK1415, 100 nM) slightly decreased cAMP levels in microglia 
from controls, while it had a significantly higher effect on microglia from APPSw,Ind mice (Fig. 
5C). Interestingly, statistical analysis showed an interaction between mice genotype and 
agonist treatment. Simultaneous activation of the two receptors led to a negative cross-talk 
both in control and APPSw,Ind animals (Fig. 5C). The effect of JWH133 on ERK1/2 
phosphorylation was significantly higher in microglia from APPSw,Ind and the analysis using 
two-way ANOVA showed an interaction between mice genotype and ligand treatment. When 
cells from APPSw,Ind  mice were pretreated with a CB2R selective antagonist (SR144528, 1 
µM) or with a GPR18 selective antagonist (PSBCB5, 1 µM), the effect of the two agonists 
was abolished, indicating a bidirectional cross-antagonism (Fig. 5D). 
To sum up, activated microglia or microglia from APPSw,Ind mice show an increase in the 
expression of CB2R, GPR18, and CB2R-GPR18 heteromers and a potentiation in specific 
signaling.  
 
4. Discussion  
 
Despite GPR18 and GPR55 may respond to cannabinoid molecules, the physiological role of 
the receptors and their signal transduction mechanisms are unclear. Neither they are real 
cannabinoid receptors nor share sequence similarity. Furthermore, pharmacological 
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characterization is very incomplete due to shortage in pharmacological tools. exist and v) the 
signal transduction mechanisms are not yet fully elucidated. In such a scenario, there is the 
possibility proven for GPR55 (Balenga et al., 2014; Martínez-Pinilla et al., 2014; Moreno et 
al., 2014) but not for GPR18 that these receptors may form heteromers with cannabinoid 
receptors. The consequences of heteroreceptor complex formation are multiple as it may 
result in cross-inhibition in some signaling pathways investigated in some expression system, 
but in potentiation in the case of activated microglia. In fact, CB2R in resting microglia are 
not well coupled to Gi, whereas in activated cells, overexpressed CB2R are robustly coupled 
to Gi and such finding correlates with a significant increase in the expression of CB1R/CB2R 
heteromers (Navarro et al., 2018a). 
GPR55 may also form heteromers with either CB1 or CB2 receptors. Two different 
laboratories demonstrated that CB2R may form heteromers with GPR55. In one of them the 
study of receptor heteromerization was linked to cancer because GPR55 is overexpressed in 
many cancerous cells (Moreno et al., 2014). The second paper showed heteromer formation 
and its signaling consequences in a heterologous expression system (Balenga et al., 2014). 
The presence of the partner receptor in the heteromer affected signal transduction from both 
CB2R and GPR18. Co-expression of CB2R and GPR55 led to a reduction in GPR55-mediated 
activation of transcription factors and DMR signal, while MAPK pathway activation was 
potentiated. When CB2R activation was assayed, co-expression of CB2R and GPR55 
negatively modulated CB2R-mediated MAPK pathway activation and DMR signals (Balenga 
et al., 2014). GPR55 may also form heteromers with CB1R as reported from work not only in 
heterologous expression systems but in rodent and non-human primate models. A significant 
amount of CB1-GPR55 heteroreceptor complexes are expressed in the corpus striatum of the 
rat, as demonstrated by detecting the heteromer print consisting of cross-antagonism, i.e. 
blockade of signaling of one receptor by the antagonist of the partner receptor in the 
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heteromeric complex. In situ PLA assays served to confirm expression of CB1R-GPR55 
complexes in the caudate and putamen nuclei of a non-human primate (Martínez-Pinilla et al., 
2014).  
The endocannabinoid system suffers profound changes in neurodegenerative diseases, 
especially in those with an inflammatory component (Bisogno and Di Marzo, 2010). CB1R 
and CB2R are both expressed in microglia, where CB2R regulates CB1R signaling, and under 
inflammatory conditions CB2R expression and signaling are upregulated, and the negative 
cross-talk between CB1R and CB2R turns into synergy when both receptors are co-activated 
(Navarro et al., 2018a). (Walter et al., 2003) demonstrated that pathological stimulation of 
microglia triggered microglial cell migration by engaging CB2R and receptors for abnormal 
cannabidiol, i.e. GPR18. GPR18 mRNA and protein expression was found in microglial cells, 
where NAGly, seemingly through GPR18, regulates migration and produces phenotypic 
switches, being a potent pro-migratory lipid (McHugh et al., 2010, 2012; McHugh, 2012).  
We here show that GPR18 may interact with cannabinoid receptors but unlike GPR55, which 
may interact with both, GPR18 establishes receptor complexes with CB2 but not with CB1 
receptors. This differential trend is relevant and shows that GPCR-GPCR interactions are not 
promiscuous, i.e. further to the need of being expressed in the same cell, the two interacting 
receptors should have complementary interfaces to be able to establish direct molecular 
contacts and display novel functional properties (Navarro et al., 2016, 2018b). The 
functionality of the CB2R-GPR18 heteromer was studied in HEK-293T cells at the level of 
different signaling pathways. In all of them (intracellular cAMP accumulation, ERK1/2 
phosphorylation and DMR), a negative cross-talk was detected, i.e. when both receptors are 
activated, the signal does not become additive but is reduced. The negative cross-talk, which 
may be considered a heteromer print, indicates that GPR18 activation places a brake to the 
action of cannabinoids acting on CB2R.  
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As CB2R is considered a receptor that may mediate neuroprotection (de Lago and Fernández-
Ruiz, 2007; Sagredo et al., 2009; Gómez-Gálvez et al., 2016),  microglia-expressed CB2R-
GPR18 receptor complexes may be targets for neuroprotection. In fact, the complex was 
expressed both in resting microglia and in primary cultures of microglia treated with 1 μM 
LPS plus 200 U/mL IFN-γ. Upon microglial activation CB2R and GPR18 expression and 
signaling were upregulated, while the negative cross-talk was maintained. In AD and in the 
APPSw,Ind mice AD model, inflammatory parameters are present in cortex and hippocampus 
(Mucke et al., 2000; Collins-Praino et al., 2014; Bronzuoli et al., 2016). Indeed the APPSw,Ind 
model of AD has been described to display reactive astrocytes and activated microglia 
(Mucke et al., 2000; Saura et al., 2005). In the microglial cultures from of APPSw,Ind mice 
brain, we found similar results to those obtained in microglia from wild-type animals treated 
with LPS/IFN-γ. Apart from the heteromer print, was found that the amount of CB2R-GPR18 
heteroreceptor complexes increased when compared to data generated using samples from 
control animals. All these data suggest that CB2R-GPR18 complexes deserve attention as 




This work is part of the PhD project of IRR, who performed many of the 
biophysical/biochemical and pharmacological assays and processed the resulting data, she 
wrote part of the methods section and edited the manuscript. GN designed and supervised the 
biophysical/biochemical and pharmacological assays and participated in manuscript 
preparation. DA performed the primary cultures of microglia and participated in some of the 
performed biophysical/biochemical and pharmacological assays.  EIC provided statistical 
  
 25 
guidance and participated in data analysis. MZ synthesized GPR18 ligands; KKK supervised 
the syntheses. CTS and CEM discovered, characterized, and designed the ligands for GPR18. 
CAS provided the transgenic animals and performed the genotyping. RF directed the work 




Authors declare no competing interests. 
 
Acknowledgements 
We would like to thank Prof. Martin Ríos for his help in statistical analysis of data and 
Jasmina Jiménez for technical help. This research was supported by grants (SAF2012-39875-
C02-01 and SAF2016-80027-R) from the Spanish Ministry of Economy and Competitiveness 
(MINECO; grants may include EU FEDER funds) and from the Fundació La Marató de TV3 
(grant number 201413330). Financial support by the Polish National Science Center DEC. 




Al Suleimani, Y.M., Al Mahruqi, A.S., 2017. The endogenous lipid N-arachidonoyl glycine is 




Balenga, N. a, Martínez-Pinilla, E., Kargl, J., Schröder, R., Peinhaupt, M., Platzer, W., Bálint, 
Z., Zamarbide, M., Dopeso-Reyes, I., Ricobaraza,  a, Pérez-Ortiz, J.M., Kostenis, E., 
Waldhoer, M., Heinemann,  a, Franco, R., 2014. Heteromerization of GPR55 and 
cannabinoid CB2 receptors modulates signaling. Br. J. Pharmacol. 1–64. 
https://doi.org/10.1111/bph.12850 
Becker, A.M., Callahan, D.J., Richner, J.M., Choi, J., DiPersio, J.F., Diamond, M.S., 
Bhattacharya, D., 2015. GPR18 Controls Reconstitution of Mouse Small Intestine 
Intraepithelial Lymphocytes following Bone Marrow Transplantation. PLOS ONE 10, 
e0133854. https://doi.org/10.1371/journal.pone.0133854 
Bilkei-Gorzo, A., 2012. The endocannabinoid system in normal and pathological brain 
ageing. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 367, 3326–3341. 
https://doi.org/10.1098/rstb.2011.0388 
Bisogno, T., Di Marzo, V., 2010. Cannabinoid receptors and endocannabinoids: role in 
neuroinflammatory and neurodegenerative disorders. CNS Neurol. Disord. Drug 
Targets 9, 564–573. https://doi.org/BSP/CDTCNSND/E-Pub/00056 [pii] 
Bradshaw, H.B., Rimmerman, N., Hu, S., Benton, V.M., Stuart, J.M., Masuda, K., Cravatt, 
B.F., O’Dell, D.K., Walker, J.M., 2009. The endocannabinoid anandamide is a 
precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. 
BMC Biochem. 10, 14. https://doi.org/10.1186/1471-2091-10-14 
Bronzuoli, M.R., Iacomino, A., Steardo, L., Scuderi, C., 2016. Targeting neuroinflammation 
in Alzheimer’s disease. J. Inflamm. Res. https://doi.org/10.2147/JIR.S86958 
Burstein, S.H., McQuain, C.A., Ross, A.H., Salmonsen, R.A., Zurier, R.E., 2011. Resolution 




Cabral, G. a, Marciano-Cabral, F., 2005. Cannabinoid receptors in microglia of the central 
nervous system: immune functional relevance. J. Leukoc. Biol. 78, 1192–7. 
https://doi.org/10.1189/jlb.0405216 
Caldwell, M.D., Hu, S.S.J., Viswanathan, S., Bradshaw, H., Kelly, M.E.M., Straiker, A., 
2013. A GPR18-based signalling system regulates IOP in murine eye. Br. J. 
Pharmacol. 169, 834–843. https://doi.org/10.1111/bph.12136 
Callén, L., Moreno, E., Barroso-Chinea, P., Moreno-Delgado, D., Cortés, A., Mallol, J., 
Casadó, V., Lanciego, J.L., Franco, R., Lluis, C., Canela, E.I., McCormick, P.J., 2012. 
Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J. Biol. 
Chem. 287, 20851–65. https://doi.org/10.1074/jbc.M111.335273 
Collins-Praino, L.E., Francis, Y.I., Griffith, E.Y., Wiegman, A.F., Urbach, J., Lawton, A., 
Honig, L.S., Cortes, E., Vonsattel, J.P.G., Canoll, P.D., Goldman, J.E., Brickman, 
A.M., 2014. Soluble amyloid beta levels are elevated in the white matter of 
Alzheimer’s patients, independent of cortical plaque severity. Acta Neuropathol. 
Commun. 2, 83. https://doi.org/10.1186/s40478-014-0083-0 
Console-Bram, L., Brailoiu, E., Brailoiu, G.C., Sharir, H., Abood, M.E., 2014. Activation of 
GPR18 by cannabinoid compounds: a tale of biased agonism: GPR18 and intracellular 
calcium, MAPK, β-arrestin. Br. J. Pharmacol. 171, 3908–3917. 
https://doi.org/10.1111/bph.12746 
de Lago, E., Fernández-Ruiz, J., 2007. Cannabinoids and neuroprotection in motor-related 
disorders. CNS Neurol. Disord. Drug Targets 6, 377–87. 
https://doi.org/10.2174/187152707783399210 
España, J., Valero, J., Miñano-Molina, A.J., Masgrau, R., Martín, E., Guardia-Laguarta, C., 
Lleó, A., Giménez-Llort, L., Rodríguez-Alvarez, J., Saura, C.A., 2010. beta-Amyloid 
disrupts activity-dependent gene transcription required for memory through the CREB 
  
 28 
coactivator CRTC1. J. Neurosci. Off. J. Soc. Neurosci. 30, 9402–9410. 
https://doi.org/10.1523/JNEUROSCI.2154-10.2010 
Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R.M., Ramos, J.A., Guzmán, M., 2007. 
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends 
Pharmacol. Sci. 28, 39–45. https://doi.org/10.1016/j.tips.2006.11.001 
Finlay, D.B., Joseph, W.R., Grimsey, N.L., Glass, M., 2016. GPR18 undergoes a high degree 
of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. PeerJ 4, 
e1835. https://doi.org/10.7717/peerj.1835 
Franco, R., Fernández-Suárez, D., 2015. Alternatively activated microglia and macrophages 
in the central nervous system. Prog. Neurobiol. 131, 65–86. 
https://doi.org/10.1016/j.pneurobio.2015.05.003 
Franklin, A., Stella, N., 2003. Arachidonylcyclopropylamide increases microglial cell 
migration through cannabinoid CB2and abnormal-cannabidiol-sensitive receptors. 
Eur. J. Pharmacol. 474, 195–198. https://doi.org/10.1016/S0014-2999(03)02074-0 
Gantz, I., Muraoka, A., Yang, Y.K., Samuelson, L.C., Zimmerman, E.M., Cook, H., Yamada, 
T., 1997. Cloning and chromosomal localization of a gene (GPR18) encoding a novel 
seven transmembrane receptor highly expressed in spleen and testis. Genomics 42, 
462–6. https://doi.org/10.1006/geno.1997.4752 
Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., García, C., 2016. Potential of the 
cannabinoid CB2 receptor as a pharmacological target against inflammation in 
Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 200–208. 
https://doi.org/10.1016/j.pnpbp.2015.03.017 
Járai, Z., Wagner, J.A., Varga, K., Lake, K.D., Compton, D.R., Martin, B.R., Zimmer, A.M., 
Bonner, T.I., Buckley, N.E., Mezey, E., Razdan, R.K., Zimmer, A., Kunos, G., 1999. 
  
 29 
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from 
CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96, 14136–14141. 
Jeong, H.-J., Vandenberg, R.J., Vaughan, C.W., 2010. N-arachidonyl-glycine modulates 
synaptic transmission in superficial dorsal horn: NAGly enhances glycine 
transmission in dorsal horn. Br. J. Pharmacol. 161, 925–935. 
https://doi.org/10.1111/j.1476-5381.2010.00935.x 
Kohno, M., Hasegawa, H., Inoue, A., Muraoka, M., Miyazaki, T., Oka, K., Yasukawa, M., 
2006. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-
protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun. 347, 827–832. 
https://doi.org/10.1016/j.bbrc.2006.06.175 
Lanciego, J.L., Barroso-Chinea, P., Rico, A.J., Conte-Perales, L., Callén, L., Roda, E., 
Gómez-Bautista, V., López, I.P., Lluis, C., Labandeira-García, J.L., Franco, R., 2011. 
Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of 
Macaca fascicularis. J. Psychopharmacol. Oxf. Engl. 25, 97–104. 
https://doi.org/10.1177/0269881110367732 
Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., Denovan-Wright, E.M., 2015. Cannabidiol is a 
negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172, 
4790–4805. https://doi.org/10.1111/bph.13250 
Lu, H.-C., Mackie, K., 2016. An Introduction to the Endogenous Cannabinoid System. Biol. 
Psychiatry 79, 516–525. https://doi.org/10.1016/j.biopsych.2015.07.028 
Lu, V.B., Puhl, H.L., Ikeda, S.R., 2013. N-Arachidonyl glycine does not activate G protein-
coupled receptor 18 signaling via canonical pathways. Mol Pharmacol 83, 267–82. 
https://doi.org/10.1124/mol.112.081182 
Martínez-Pinilla, E., Reyes-Resina, I., Oñatibia-Astibia, A., Zamarbide, M., Ricobaraza, A., 
Navarro, G., Moreno, E., Dopeso-Reyes, I.G.G., Sierra, S., Rico, A.J.J., Roda, E., 
  
 30 
Lanciego, J.L.L., Franco, R., 2014. CB1 and GPR55 receptors are co-expressed and 
form heteromers in rat and monkey striatum. Exp. Neurol. 261, 44–52. 
https://doi.org/10.1016/j.expneurol.2014.06.017 
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, 
C., Oyarzabal, J., Canela, E.I., Lanciego, J.L., Nadal, X., Navarro, G., Borea, P.A., 
Franco, R., 2017. Binding and Signaling Studies Disclose a Potential Allosteric Site 
for Cannabidiol in Cannabinoid CB2 Receptors. Front. Pharmacol. 8, 744. 
https://doi.org/10.3389/fphar.2017.00744 
Matouk, A.I., Taye, A., El-Moselhy, M.A., Heeba, G.H., Abdel-Rahman, A.A., 2017. The 
Effect of Chronic Activation of the Novel Endocannabinoid Receptor GPR18 on 
Myocardial Function and Blood Pressure in Conscious Rats. J. Cardiovasc. 
Pharmacol. 69, 23–33. https://doi.org/10.1097/FJC.0000000000000438 
McHugh, D., 2012. GPR18 in microglia: Implications for the CNS and endocannabinoid 
system signalling. Br. J. Pharmacol. https://doi.org/10.1111/j.1476-5381.2012.02019.x 
McHugh, D., Hu, S.S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J.M., Bradshaw, H.B., 
2010. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed 
cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC 
Neurosci. 11, 44. https://doi.org/10.1186/1471-2202-11-44 
McHugh, D., Wager-Miller, J., Page, J., Bradshaw, H.B., 2012. siRNA knockdown of GPR18 
receptors in BV-2 microglia attenuates <em>N</em>-arachidonoyl glycine-induced 
cell migration. J. Mol. Signal. 7, 10. https://doi.org/10.1186/1750-2187-7-10 
Miller, S., Leishman, E., Oehler, O., Daily, L., Murataeva, N., Wager-Miller, J., Bradshaw, 
H., Straiker, A., 2016. Evidence for a GPR18 role in diurnal regulation of intraocular 




Moreno, E., Andradas, C., Medrano, M., Caffarel, M.M., Pérez-Gómez, E., Blasco-Benito, S., 
Gómez-Cañas, M., Pazos, M.R., Irving, A.J., Lluís, C., Canela, E.I., Fernández-Ruiz, 
J., Guzmán, M., McCormick, P.J., Sánchez, C., 2014. Targeting CB2-GPR55 receptor 
heteromers modulates cancer cell signaling. J. Biol. Chem. 289, 21960–21972. 
https://doi.org/10.1074/jbc.M114.561761 
Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., 
Kholodenko, D., Johnson-Wood, K., McConlogue, L., 2000. High-level neuronal 
expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic 
mice: synaptotoxicity without plaque formation. J. Neurosci. Off. J. Soc. Neurosci. 20, 
4050–4058. 
Navarro, G., Borroto-Escuela, D., Angelats, E., Etayo, Í., Reyes-Resina, I., Pulido-Salgado, 
M., Rodriguez-Perez, A.I., Canela, E.I., Saura, J., Lanciego, J.L., Labandeira-García, 
J.L., Saura, C.A., Fuxe, K., Franco, R., 2018a. Receptor-heteromer mediated 
regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 
receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. 
Brain. Behav. Immun. 67, 139–151. https://doi.org/10.1016/j.bbi.2017.08.015 
Navarro, G., Cordomi, A., Brugarolas, M., Moreno, E., Aguinaga, D., Pérez-Benito, L., Ferre, 
S., Cortés, A., Casadó, V., Mallol, J., Canela, E.I., Lluis, C., Pardo, L., McCormick, 
P., Franco, R., 2018b. Cross-communication between Gi and Gs in a G-protein-
coupled receptor heterotetramer guided by a receptor C-terminal domain. BMC 
Biology p.In the press. 
Navarro, G., Cordomí, A., Zelman-Femiak, M., Brugarolas, M., Moreno, E., Aguinaga, D., 
Perez-Benito, L., Cortés, A., Casadó, V., Mallol, J., Canela, E.I., Lluís, C., Pardo, L., 
García-Sáez, A.J., McCormick, P.J., Franco, R., 2016. Quaternary structure of a G-
  
 32 
protein-coupled receptor heterotetramer in complex with Gi and Gs. BMC Biol. 14, 
26. https://doi.org/10.1186/s12915-016-0247-4 
Navarro, G., Hradsky, J., Lluís, C., Casadó, V., McCormick, P.J., Kreutz, M.R., Mikhaylova, 
M., 2012. NCS-1 associates with adenosine A(2A) receptors and modulates receptor 
function. Front. Mol. Neurosci. 5, 53. https://doi.org/10.3389/fnmol.2012.00053 
Pacher, P., Mechoulam, R., 2011. Is lipid signaling through cannabinoid 2 receptors part of a 
protective system? Prog. Lipid Res. 50, 193–211. 
https://doi.org/10.1016/j.plipres.2011.01.001 
Parmar, N., Ho, W.-S.V., 2010. N-arachidonoyl glycine, an endogenous lipid that acts as a 
vasorelaxant via nitric oxide and large conductance calcium-activated potassium 
channels: Vascular actions of N-arachidonoyl glycine. Br. J. Pharmacol. 160, 594–
603. https://doi.org/10.1111/j.1476-5381.2009.00622.x 
Penumarti, A., Abdel-Rahman, A.A., 2014. The Novel Endocannabinoid Receptor GPR18 Is 
Expressed in the Rostral Ventrolateral Medulla and Exerts Tonic Restraining 
Influence on Blood Pressure. J. Pharmacol. Exp. Ther. 349, 29–38. 
https://doi.org/10.1124/jpet.113.209213 
Qin, Y., Verdegaal, E.M.E., Siderius, M., Bebelman, J.P., Smit, M.J., Leurs, R., Willemze, R., 
Tensen, C.P., Osanto, S., 2011. Quantitative expression profiling of G-protein-coupled 
receptors (GPCRs) in metastatic melanoma: The constitutively active orphan GPCR 
GPR18 as novel drug target. Pigment Cell Melanoma Res. 24, 207–218. 
https://doi.org/10.1111/j.1755-148X.2010.00781.x 
Regard, J.B., Sato, I.T., Coughlin, S.R., 2008. Anatomical Profiling of G Protein-Coupled 
Receptor Expression. Cell 135, 561–571. https://doi.org/10.1016/j.cell.2008.08.040 
Rempel, V., Atzler, K., Behrenswerth, A., Karcz, T., Schoeder, C., Hinz, S., Kaleta, K., 
Thimm, D., Kiec-Kononowiczb, K., Müller, C.E., 2014. Bicyclic imidazole-4-one 
  
 33 
derivatives: a new class of antagonists for the orphan G protein-coupled receptors 
GPR18 and GPR55. Med Chem Commun 5, 632–649. 
Sagredo, O., González, S., Aroyo, I., Pazos, M.R., Benito, C., Lastres-Becker, I., Romero, 
J.P., Tolón, R.M., Mechoulam, R., Brouillet, E., Romero, J., Fernández-Ruiz, J., 2009. 
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: 
Relevance for Huntington’s disease. GLIA 57, 1154–1167. 
https://doi.org/10.1002/glia.20838 
Saura, C.A., Chen, G., Malkani, S., Choi, S.-Y., Takahashi, R.H., Zhang, D., Gouras, G.K., 
Kirkwood, A., Morris, R.G.M., Shen, J., 2005. Conditional inactivation of presenilin 1 
prevents amyloid accumulation and temporarily rescues contextual and spatial 
working memory impairments in amyloid precursor protein transgenic mice. J. 
Neurosci. Off. J. Soc. Neurosci. 25, 6755–6764. 
https://doi.org/10.1523/JNEUROSCI.1247-05.2005 
Schoeder, C.T., 2017. Identification, optimization and characterization of pharmacological 
tools for the cannabinoid-activated orphan G protein-coupled receptor GPR18 and 
related receptors. PhD Thesis. University of Bonn. Bonn, Germany., Bonn, Germany. 
Sierra, S., Luquin, N., Rico, A.J., Gómez-Bautista, V., Roda, E., Dopeso-Reyes, I.G., 
Vázquez, A., Martínez-Pinilla, E., Labandeira-García, J.L., Franco, R., Lanciego, J.L., 
2015. Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output 
neurons in macaques: changes following experimental parkinsonism. Brain Struct. 
Funct. 220, 2721–38. https://doi.org/10.1007/s00429-014-0823-8 
Takenouchi, R., Inoue, K., Kambe, Y., Miyata, A., 2012. N-arachidonoyl glycine induces 




Vassilatis, D.K., Hohmann, J.G., Zeng, H., Li, F., Ranchalis, J.E., Mortrud, M.T., Brown, A., 
Rodriguez, S.S., Weller, J.R., Wright, A.C., Bergmann, J.E., Gaitanaris, G.A., 2003. 
The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. 
Sci. 100, 4903–4908. https://doi.org/10.1073/pnas.0230374100 
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., Stella, N., 
2003. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. 
Neurosci. Off. J. Soc. Neurosci. 23, 1398–405. 
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D.G., Caldwell, J.S., 
Chen, Y.A., 2009. Lipid G protein-coupled receptor ligand identification using β-
arrestin PathHunter
TM







Figure 1. Molecular interaction between CB2 and GPR18 receptors in living cells. 
Confocal microscopy images of HEK-293T cells transfected with CB1R-YFP, CB2R-YFP or 
GPR18-Rluc alone, or co-transfected with CB1R-YFP and GPR18-Rluc or with CB2R-YFP 
and GPR18-Rluc. GPR18 receptors (red) were identified by immunocytochemistry using anti-
Rluc antibodies and CB1R and CB2R receptors (green) were identified by the fluorescence of 
YFP-containing fusion proteins (A). Co-localization is shown in the panels in the right 
(yellow). Cell nuclei were stained with Hoechst (blue channel). Scale bar: 10 µm. Correct 
functionality of the fusion proteins used in BRET assays assessed by intracellular cAMP 
determination assays (B). HEK-293T cells were transfected with cDNA encoding for CB1R, 
CB1R-YFP, CB2R, CB2R-YFP, GPR18 or GPR18-Rluc (1 µg cDNA) and cAMP production 
was determined after stimulation with 0.5 µM forskolin in the absence (100%) or presence of 
200 mM ACEA (for CB1R and CB1R-YFP), 200 mM JWH133 (for CB2R and CB2R-YFP) or 
30 nM PSBKK1415 (for GPR18 and GPR18-Rluc). Percentage of effect respect to the 
increase in cAMP levels achieved by 0.5 μM forskolin is represented. Results are the mean ± 
S.D. from 5 independent experiments performed in triplicates. No significant differences were 
found after Student’s t test between effect in cells expressing the non-fused receptor or 
expressing the corresponding fusion protein. BRET saturation experiments performed using 
HEK-293T cells co-transfected with (C): GPR18-Rluc cDNA (1.6 µg) and increasing 
amounts of CB1R-YFP cDNA (0 to 2 µg cDNA), (D): GPR18-Rluc cDNA (1.6 µg) and 
increasing amounts of CB2R-YFP cDNA (0 to 2 µg cDNA), or (E): CB1R-Rluc cDNA (1 µg) 
and increasing amounts of CB2R-YFP cDNA (0 to 2.5 µg cDNA) as positive control (squares) 
and GABAB-Rluc cDNA (0.5 µg) and increasing amounts of GPR18-YFP cDNA (0 to 3 µg 
cDNA) as a negative control (circles). The relative amount of BRET acceptor is given as the 
ratio between the fluorescence of the acceptor minus the fluorescence detected in cells only 
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expressing the donor and the luciferase activity of the donor (YFP/Rluc). BRET data are 
expressed as the mean ± S.D. of six different experiments performed in duplicates. mBU: 
milliBret units.  
Figure 2. cAMP levels and pERK responses in single transfected cells. HEK-293T cells 
transfected with cDNA encoding for CB2R (A, C) or GPR18 (B, D) were treated with 
increasing concentrations of JWH133 for CB2R or PSBKK1415 for GPR18. cAMP 
accumulation (A, B) was detected by TR-FRET in the presence of 0.5 μM forskolin. cAMP 
production is expressed as % of levels obtained by 0.5 µM forskolin. ERK1/2 
phosphorylation (C, D) was analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). 
ERK1/2 phosphorylation data are expressed as % respect to basal levels. Values are the mean 
± S.D. of 5 different experiments performed in triplicates. One-way ANOVA followed by 
Bonferroni’s multiple comparison post hoc test were used for statistical analysis. (**p < 0.01, 
***p < 0.001; versus treatment with forskolin in cAMP or untreated cells in pERK assays). 
 
Figure 3. Signaling in HEK-293T cells expressing CB2R and/or GPR18. HEK-293T cells 
transfected with cDNA encoding for CB2R (A, D, G), for GPR18 (B, E, H) or both (C, F, I) 
were pre-treated with a selective receptor antagonist (1 μM SR144528 for CB2R or 1 μM 
PSBCB5 for GPR18) and subsequently treated with selective agonists (100 nM JWH133 for 
CB2R or 30 nM PSBKK1415 for GPR18), alone or in combination. cAMP accumulation (A-
C) was detected by TR-FRET in the presence of 0.5 μM forskolin. cAMP production is 
expressed as % of levels obtained by 0.5 µM forskolin. ERK1/2 phosphorylation (D-F) was 
analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2 phosphorylation data 
are expressed as % respect to basal levels. In cAMP accumulation and MAPK signaling 
assays, values are the mean ± S.D. of 8 different experiments performed in triplicates, and 
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one-way ANOVA followed by Bonferroni’s multiple comparison post hoc test were used for 
statistical analysis. (*p < 0.05, **p < 0.01, ***p < 0.001; versus treatment with forskolin in 
cAMP or basal in pERK assays). (##p < 0.01, ###p < 0.001; versus treatment with JWH133 
alone). (&p < 0.05, &&p < 0.01, &&&p < 0.001; versus treatment with PSBKK1415 alone). 
(G-I): DMR tracings representing the picometer-shifts of reflected light wavelength (in pm) 
over time upon ligand treatment: JWH133 (red), PSBKK1415 (dark blue), JWH133 + 
PDBKK1415 (purple), SR144528 + JWH133 (pink), SR144528 + PSBKK1415 (orange), 
PSBCB5 + JWH133 (green), PSBCB5 + PSBKK1415 (light blue). 
 
Figure 4. Detection of the CB2-GPR18 receptor heteromers in primary microglial 
cultures. Proximity Ligation Assay (PLA) was performed as described in Methods in primary 
cultures of microglial cells incubated for 48 h in the absence or presence of 1 μM LPS and 
200 U/mL IFN-γ using specific primary antibodies against CB2R and GPR18. Representative 
images corresponding to stacks of 5 sequential planes are shown in A. Cell nuclei were 
stained with Hoechst (blue) and heteroreceptor clusters appear as red dots. Scale bar: 20 μm. 
(B): Ratio (r; number of red spots/cell-containing spots) and percentage of cells containing 
one or more red spots (numbers above each bar) are the mean ± S.D. of counts in 4 different 
fields from every sample (n=5). No significant differences were found between untreated 
(white bars) and LPS plus IFN-γ (black bars) conditions neither in the number of red 
spots/cell-containing spots nor in the percentage of cells containing one or more red spots. 
Primary cultures of microglia were incubated for 48 h with medium or with medium 
containing 1 μM LPS and 200 U/mL IFN-γ (C). Relative gene expression of CB2R and 
GPR18 was measured by real time-PCR. Data represent 2
-Ct
, and data are the mean ± S.D. 
of 6 different experiments (different cell cultures) performed in triplicates. Student’s t-test 
(paired) was used for statistical analysis. (*p < 0.05, **p < 0.01; versus untreated). Primary 
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cultures of microglia were incubated for 48 h with medium (white bars) or with medium 
containing 1 μM LPS plus 200 U/mL IFN-γ (black bars). Cells were then pre-treated with 
selective receptor antagonists (1 μM SR144528 for CB2R or 1 μM PSBCB5 for GPR18) and 
subsequently treated with selective agonists (100 nM JWH133 for CB2R or 30 nM 
PSBKK1415 for GPR18), alone or in combination. cAMP accumulation (D) was detected by 
TR-FRET in the presence of 0.5 μM forskolin. cAMP production is expressed as % of levels 
obtained by 0.5 µM forskolin. ERK1/2 phosphorylation (E) was analyzed using an 
AlphaScreen®SureFire® kit (Perkin Elmer). ERK1/2 phosphorylation data are expressed as 
% respect to basal levels. Panels D, E: Values are the mean ± S.D. of 6 different experiments 
performed in triplicates. Two-way ANOVA for factors ligand and resting/LPS plus 200 U/mL 
IFN-γ showed statistical differences (#p < 0.05, ###p < 0.001). One-way ANOVA followed 
by Bonferroni’s multiple comparison post-hoc test showed statistical differences: individual 
treatment versus 0.5 µM forskolin in cAMP or versus basal in pERK (*p < 0.05, ***p < 
0.001), or combined versus individual treatment (&p < 0.05, &&&p < 0.001). 
 
Figure 5. CB2-GPR18 receptor heteromer expression and function in primary cultures 
of microglia from the APPSw,Ind mice. Proximity Ligation Assay (PLA) was performed as 
described in Methods in primary cultures of microglia cells from two-day-old wild-type 
(control) and APPSw,Ind mice using specific primary antibodies against CB2R and GPR18. 
Representative images corresponding to stacks of 5 sequential planes are shown (A). Cell 
nuclei were stained with Hoechst (blue) and heteroreceptor complexes appear as red dots. 
Scale bar: 20 μm. (B) Ratio (r; number of red spots/cell-containing spots) and percentage of 
cells containing one or more red spots (numbers above each bar graphs) are the mean ± S.D. 
of counts in 4 different fields from every sample (n=5). Two-way ANOVA for factors red 
dots and control (white bars)/APPSw,Ind (black bars) showed statistical differences (#p < 0.05). 
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Panels C, D: Primary cultures of microglial cells of two-day-old wild-type (control, white 
bars) and APPSw,Ind (black bars) mice were pre-treated with selective receptor antagonists (1 
μM SR144528 for CB2R or 1 μM PSBCB5 for GPR18) and subsequently treated with 
selective agonists (300 nM JWH133 for CB2R or 100 nM PSBKK1415 for GPR18), alone or 
in combination. cAMP accumulation (C) was detected by TR-FRET in the presence of 0.5 
μM forskolin. cAMP production is expressed as % of levels obtained by 0.5 µM forskolin. 
ERK1/2 phosphorylation (D) was analyzed using an AlphaScreen®SureFire® kit (Perkin 
Elmer) ERK1/2 phosphorylation data are expressed as % respect to basal levels. Values are 
the mean ± S.D. of 6 different experiments performed in triplicates. Two-way ANOVA for 
factors ligand and control/APPSw,Ind showed statistical differences (#p < 0.05, ###p < 0.001). 
One-way ANOVA followed by Bonferroni’s multiple comparison post-hoc test showed 
statistical differences: individual treatment versus 0.5 µM forskolin in cAMP or versus basal 
in pERK (***p < 0.001) or combined versus individual treatment (&p < 0.05, &&p < 0.01, 
&&&p < 0.001). 
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